Gain market access in Japan with JPAL and PMDA approval

Japanese Pharmaceutical Affairs Law (JPAL) regulations

Japan-flagThe distribution of medical devices in Japan is regulated in accordance with the Japanese Pharmaceutical Affairs Law (JPAL) by the Ministry of Health, Labour and Welfare (MHLW).  Revision of the Pharmaceutical Affairs Law was enforced on April 1, 2005 which included third party certification systems for Class II medical devices.

Because of the complexities of JPAL and the involvement of Japanese and international governmental bodies, we can help you understand device classifications, prepare for the review process, and help you meet standards.


Pharmaceutical and Medical Devices Agency (PMDA) review process

Under JPAL, the Pharmaceutical and Medical Devices Agency (PMDA) review process depends on the classification of the medical device, which is generally in line with the principles outlined by the International Medical Device Regulators Forum:

Class I General Medical Devices: Pre-Market Submission (Todokede)

  • Devices of low risk to the human body
  • Approval of the product is not required, but marketing notification (Todokede) to PMDA is necessary

Class II Controlled Medical Devices: Pre-Market Certification (Ninsho)

  • Low risk to the human body
  • The majority of these devices for which certification standards have been established by MHLW, are eligible for third-party review and certification by a Registered Certification Body, such as BSI. Those devices for which no applicable certification standard has been established must be submitted to PMDA for approval (Shonin) by MHLW

Class III and IV Specially Controlled Medical Devices: Pre-Market Approval (Shonin)

  • Medium risk to human body, high risk to human body, highly invasive to patients
  • MHLW approval (shonin) is required for Class III and IV devices, based on approval standards for devices for which such standards have been established, or based on  review guidelines


How can BSI help you achieve compliance with JPAL regulations?

We are one of four Registered Certification Bodies (RCB) that is authorized to conduct certifications by the MHLW for all types of Class II Designate Controlled Medical Devices and In-Vitro Diagnostic Reagents. We also provide a number of solutions for our global customers wishing to access the Japanese market. So as your company grows and expands sales into overseas markets, we can help you meet the increasingly complex regulatory schemes and certifications.

Streamlined audits can help save you money

We have auditors qualified to conduct MO 169 audits in Asia, Europe and the Americas, and can combine the required JPAL audits with our clients’ ISO 13485 and Notified Body audits, streamlining the process. And to help save you from additional audits, our reports covering ISO 13485 and MO 169 are accepted by other RCBs for use in conjunction with their reviews of product submissions from their Market Authorization Holder (MAHs).

Helping smaller companies overcome global challenges

Newly established or smaller companies may have a challenge obtaining a Japan-based Market Authorization Holder (MAH) with GQP & GVP capability to hold the marketing approval. Japan has harmonized the QMS requirements with ISO 13485, but there are additional requirements that will fall under the responsibility of overseas manufacturers under Ministerial Ordinances’ requirements for accreditation. With experience working with companies of all sizes, we can help you break into this highly regulated yet profitable overseas market.

Our core competencies and unique skills are calibrated to handle our customer’s extensive portfolio of medical technologies which include: